BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) 2014;7:169-78. [PMID: 24282255 DOI: 10.1158/1940-6207.CAPR-13-0299] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Blagosklonny MV. The goal of geroscience is life extension. Oncotarget 2021;12:131-44. [PMID: 33613842 DOI: 10.18632/oncotarget.27882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Warner HR. NIA's Intervention Testing Program at 10 years of age. Age (Dordr) 2015;37:22. [PMID: 25726185 DOI: 10.1007/s11357-015-9761-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
3 Leontieva OV, Blagosklonny MV. Gerosuppression in confluent cells. Aging (Albany NY) 2014;6:1010-8. [PMID: 25585637 DOI: 10.18632/aging.100714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 2017;187:53-63. [PMID: 27690272 DOI: 10.1111/cei.12875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
5 Leontieva OV, Demidenko ZN, Blagosklonny MV. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget 2015;6:23238-48. [PMID: 26177051 DOI: 10.18632/oncotarget.4836] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
6 Blagosklonny MV. Anti-aging: senolytics or gerostatics (unconventional view). Oncotarget 2021;12:1821-35. [PMID: 34504654 DOI: 10.18632/oncotarget.28049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Hassani B, Goshtasbi G, Nooraddini S, Firouzabadi N, Corte-real M. Pharmacological Approaches to Decelerate Aging: A Promising Path. Oxidative Medicine and Cellular Longevity 2022;2022:1-25. [DOI: 10.1155/2022/4201533] [Reference Citation Analysis]
8 Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Comparison of rapamycin schedules in mice on high-fat diet. Cell Cycle 2014;13:3350-6. [PMID: 25485580 DOI: 10.4161/15384101.2014.970491] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
9 Parihar M, Dodds SG, Javors M, Strong R, Hasty P, Sharp ZD. Sex-dependent lifespan extension of Apc Min/+ FAP mice by chronic mTOR inhibition. Aging Pathobiol Ther 2020;2:187-94. [PMID: 33834178 DOI: 10.31491/apt.2020.12.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Svatek RS, Ji N, de Leon E, Mukherjee NZ, Kabra A, Hurez V, Nicolas M, Michalek JE, Javors M, Wheeler K, Sharp ZD, Livi CB, Shu ZJ, Henkes D, Curiel TJ. Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer. Cancer Immunol Res 2019;7:466-75. [PMID: 30563829 DOI: 10.1158/2326-6066.CIR-18-0336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Blagosklonny MV. DNA- and telomere-damage does not limit lifespan: evidence from rapamycin. Aging (Albany NY) 2021;13:3167-75. [PMID: 33578394 DOI: 10.18632/aging.202674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Birkisdóttir MB, Jaarsma D, Brandt RMC, Barnhoorn S, van Vliet N, Imholz S, van Oostrom CT, Nagarajah B, Portilla Fernández E, Roks AJM, Elgersma Y, van Steeg H, Ferreira JA, Pennings JLA, Hoeijmakers JHJ, Vermeij WP, Dollé MET. Unlike dietary restriction, rapamycin fails to extend lifespan and reduce transcription stress in progeroid DNA repair-deficient mice. Aging Cell 2021;20:e13302. [PMID: 33484480 DOI: 10.1111/acel.13302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
13 Parihar M, Dodds SG, Hubbard G, Javors MA, Strong R, Hasty P, Sharp ZD. Rapamycin Extends Life Span in ApcMin/+ Colon Cancer FAP Model. Clin Colorectal Cancer 2021;20:e61-70. [PMID: 33132009 DOI: 10.1016/j.clcc.2020.08.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Lelegren M, Liu Y, Ross C, Tardif S, Salmon AB. Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate. Pathobiol Aging Age Relat Dis. 2016;6:31793. [PMID: 27341957 DOI: 10.3402/pba.v6.31793] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
15 Christy B, Demaria M, Campisi J, Huang J, Jones D, Dodds SG, Williams C, Hubbard G, Livi CB, Gao X, Weintraub S, Curiel T, Sharp ZD, Hasty P. p53 and rapamycin are additive. Oncotarget 2015;6:15802-13. [PMID: 26158292 DOI: 10.18632/oncotarget.4602] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
16 Liss MA, Rickborn L, Digiovanni J, Bacich D, Degraffenried LA, Parihar M, Thompson IM, Sharp ZD. mTOR inhibitors for treatment of low-risk prostate cancer. Medical Hypotheses 2018;117:63-8. [DOI: 10.1016/j.mehy.2018.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell 2016;15:28-38. [PMID: 26463117 DOI: 10.1111/acel.12405] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 18.2] [Reference Citation Analysis]
18 Dao V, Pandeswara S, Liu Y, Hurez V, Dodds S, Callaway D, Liu A, Hasty P, Sharp ZD, Curiel TJ. Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. Cancer Prev Res (Phila) 2015;8:400-9. [PMID: 25736275 DOI: 10.1158/1940-6207.CAPR-14-0313-T] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
19 Lee JY, Kennedy BK, Liao CY. Mechanistic target of rapamycin signaling in mouse models of accelerated aging. J Gerontol A Biol Sci Med Sci 2020;75:64-72. [PMID: 30900725 DOI: 10.1093/gerona/glz059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci 2014;71:4325-46. [PMID: 25015322 DOI: 10.1007/s00018-014-1677-1] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 12.4] [Reference Citation Analysis]
21 Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY) 2019;11:8048-67. [PMID: 31586989 DOI: 10.18632/aging.102355] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
22 Hasty P, Campisi J, Sharp ZD. Do p53 stress responses impact organismal aging? Transl Cancer Res 2016;5:685-91. [PMID: 30984573 DOI: 10.21037/tcr.2016.12.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K, Hui J, Jarvie C, Johnson BM, Letexier N, McCanta L, Sangesland M, Tamis O, Uhde L, Van Den Ende A, Rabinovitch PS, Suh Y, Kaeberlein M. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet 2015;6:247. [PMID: 26257774 DOI: 10.3389/fgene.2015.00247] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
24 Chariou PL, Ortega-Rivera OA, Steinmetz NF. Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients. ACS Nano 2020;14:2678-701. [PMID: 32125825 DOI: 10.1021/acsnano.0c00173] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 32.5] [Reference Citation Analysis]
25 Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. Exp Gerontol 2015;68:51-8. [PMID: 25481271 DOI: 10.1016/j.exger.2014.12.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 9.0] [Reference Citation Analysis]
26 Leontieva OV, Blagosklonny MV. Gerosuppression by pan-mTOR inhibitors. Aging (Albany NY) 2016;8:3535-51. [PMID: 28077803 DOI: 10.18632/aging.101155] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
27 Ross CN, Salmon AB. Aging research using the common marmoset: Focus on aging interventions. Nutr Healthy Aging 2019;5:97-109. [PMID: 33817407 DOI: 10.3233/nha-180046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
28 Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Ther 2014;15:586-92. [PMID: 24556924 DOI: 10.4161/cbt.28164] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
29 Dodds SG, Parihar M, Javors M, Nie J, Musi N, Dave Sharp Z, Hasty P. Acarbose improved survival for Apc+/Min mice. Aging Cell 2020;19:e13088. [PMID: 31903726 DOI: 10.1111/acel.13088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
30 Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, Bergman M, Orihuela CJ, Galvan V, Padrón Á, Drerup J, Liu Y, Hasty P, Sharp ZD, Curiel TJ. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell 2015;14:945-56. [PMID: 26315673 DOI: 10.1111/acel.12380] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 9.0] [Reference Citation Analysis]
31 He K, Zheng X, Li M, Zhang L, Yu J. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene. 2016;35:148-157. [PMID: 25867072 DOI: 10.1038/onc.2015.79] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
32 Ross CN, Austad S, Brasky K, Brown CJ, Forney LJ, Gelfond JA, Lanford R, Richardson A, Tardif SD. The development of a specific pathogen free (SPF) barrier colony of marmosets (Callithrix jacchus) for aging research. Aging (Albany NY) 2017;9:2544-58. [PMID: 29227963 DOI: 10.18632/aging.101340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
33 Dodds SG, Livi CB, Parihar M, Hsu HK, Benavides AD, Morris J, Javors M, Strong R, Christy B, Hasty P, Sharp ZD. Adaptations to chronic rapamycin in mice. Pathobiol Aging Age Relat Dis 2016;6:31688. [PMID: 27237224 DOI: 10.3402/pba.v6.31688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
34 Dao V, Liu Y, Pandeswara S, Svatek RS, Gelfond JA, Liu A, Hurez V, Curiel TJ. Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells. Cancer Res 2016;76:5970-82. [PMID: 27569211 DOI: 10.1158/0008-5472.CAN-16-0091] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
35 Sataranatarajan K, Ikeno Y, Bokov A, Feliers D, Yalamanchili H, Lee HJ, Mariappan MM, Tabatabai-Mir H, Diaz V, Prasad S, Javors MA, Ghosh Choudhury G, Hubbard GB, Barnes JL, Richardson A, Kasinath BS. Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes. J Gerontol A Biol Sci Med Sci 2016;71:850-7. [PMID: 26442901 DOI: 10.1093/gerona/glv170] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
36 Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A. Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. J Cancer Prev 2021;26:71-82. [PMID: 33842408 DOI: 10.15430/JCP.2021.26.1.71] [Reference Citation Analysis]
37 Rodriguez KA, Dodds SG, Strong R, Galvan V, Sharp ZD, Buffenstein R. Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice. Front Mol Neurosci 2014;7:83. [PMID: 25414638 DOI: 10.3389/fnmol.2014.00083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]